VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor mediated inhibition of cytokine production
| Project/Area Number |
14570477
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
ITO Tetsuhide Kyushu University, Faculty of Medicine, Research Associate, 大学院・医学研究院, 助手 (50253448)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ARITA Yoshiyuki Kyushu University, Faculty of Medicine, Research Associate, 大学院・医学研究院, 助手 (10294927)
|
|---|
| Project Period (FY) |
2002 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2004: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 2003: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2002: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | VIP / VPAC receptor / acute pancreatitis / monocyte / cytokine / Monocyte / Cytokine / 免疫担当細胞 / Vasoactive intestinal peptide / 急性膵炎の治療 / サイトカイン |
|---|
| Research Abstract |
Background & Aims : VIP receptor has been clarified to exist on immune cells, indicating it is possible involvement in immunity and inflammatory response. Therefore, we investigated the effects of VIP and selective agonists for two subtypes of VIP receptor (VPAC1-R and VPAC2-R agonist) on acute pancreatitis. Methods : Acute pancreatitis was induced in mice by four intraperitoneal injections of Caerulein and an injection of LPS. VIP,VPAC1-R agonist, VPAC2-R agonist or secretin (5nmol/body) was administered 30 minutes before and after the administration of LPS. Serum amylase and cytokine levels were determined and histological changes were evaluated. In vitro, IL-6 and TNF-a production by monocytes from the spleen was determined under the stimulation of LPS with VIP,VPAC1-R agonist or VPAC2-R agonist, and the expression of VPAC1-R and VPAC2-R mRNA in monocytes was examined. Results : VPAC1-R agonist significantly decreased serum amylase, IL-6 and TNF-a whereas VPAC2-R agonist markedly increased serum amylase. Histologically, VIP and VPAC1-R agonist attenuated pancreatitis although VPAC2-R agonist or secretin showed no significant effect. In vitro, VPAC1-R and VPAC2-R mRNA were obviously expressed in monocytes. Under the stimulation with LPS,VIP presented a biphasic pattern that once decreased IL-6 production from monocytes, and then enhanced at high concentration. VPAC1-R agonist reduced IL-6 levels, whereas VPAC2-R agonist increased IL-6 dose-dependently. VPAC1-R agonist reduced TNF-a levels in a dose dependent manner. Conclusions : VIP attenuated the experimental acute pancreatitis enzymatically and morphologically by inhibiting pro-inflammatory cytokine production from monocytes mainly through the VPAC1-R.
|
Report
(4 results)
Research Products
(18 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Elucidation of vasoactive intestinal peptide pharmacophore for VPAC1 receptors in human, rat, and guinea pig.2002
Author(s)
Ito T, Igarashi H, (equal contribution), Hou W, Mantey SA, Pradhan TK, Ulrich II CD, Hocart SJ, Coy DH, Jensen RT.
-
Journal Title
J Pharmacol Exp Ther 301
Pages: 37-50
Description
「研究成果報告書概要(欧文)」より
Related Report
-
-
-
